Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
Browse this week's featured selection of scientific publications
A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are are a few highlights from this week.
Ide-cel in R/R myeloma: patient-reported outcomes and resistance
Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the details of a number of studies investigating idecabtagene vicleucel (ide-cel), a BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy, in relapsed/refractory (R/R) multiple myeloma patients.
Comparing efficacy outcomes of ide-cel versus conventional care in R/R myeloma
Nina Shah, MD, University of California-San Francisco, San Francisco, CA, discusses an analysis that compared efficacy outcomes seen in the MAMMOTH study, a retrospective observational study of conventional care regimens, and the KarMMA trial (NCT03361748) of the BCMA-targeted CAR-T cell therapy idecabtagene vicleucel (ide-cel), both in triple-class refractory multiple myeloma patients.
Subanalysis of KarMMA study (idecabtagene vicleucel in MM) and updated results o...
In an interview with Targeted Oncology, Jesus G. Berdeja, MD, discussed a subanalysis of the KarMMA study and updated results from CARTITUDE-1, which provide insights on the use CAR T-cell therapy in heavily pretreated patients with multiple myeloma, including the elderly and frail.
Impact of age on ide-cel efficacy in the KarMMa trial
Jesus Berdeja, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the updated results from KarMMa (NCT03361748), a study aiming to evaluate the efficacy and safety of idecabtagene vicleucel (ide-cel, bb2121) in relapsed/refractory (R/R) multiple myeloma.